Researchers at the Statens Serum Institut in Denmark published a pre-print study suggesting that the second doses of Pfizer and Moderna vaccines may increase people’s likelihood of infection after 90 to 150 days. The same study suggested that a third Pfizer shot re-establishes efficacy for an indefinite period.

The large number of so-called breakthrough infections after second doses of vaccines suggest that vaccine clinical trials may have badly miscalculated efficacy rates.

The Danish Study

The study, which was published in December on the Medrxiv pre-print to await peer-review, explores SARS-CoV-2 protection against infection by the Omicron or Delta variants five months after one dose of the Pfizer or Moderna vaccines.

Lead author, Dr. Christian Holm Hansen, assistant professor of Medical Statistics and Epidemiology at the London School of Hygiene and Tropical Medicine, and his co-authors are affiliated with the Department of Infectious Disease Epidemiology and Prevention and the Department of Infectious Disease Preparedness, Statens Serum Institut, Denmark. The study received no external funding. 

The authors extracted data of positive polymerase chain reaction, …

Quality journalism costs money to produce. We will be reinvesting the proceeds of these subscriptions into an increasing volume of high quality, independent, unbiased reporting and expert analysis. Our subscription tiers use the ‘honor system’  – please do not abuse it. All tiers of service provide the same level of access to content.  We are grateful for all of you, and we hope you reciprocate.

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

TrialSite Staff

Read Source